Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Treatment Resistant Late-Life Depression
NCT02556606Phase 3Completed
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2015
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in major depressive disorder (MDD), sponsored by VA Office of Research & Development. Started Oct 2015; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02556606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02556606.